Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Clinical Therapeutics

Isavuconazole in the Treatment of Coccidioidal Meningitis

Arash Heidari, Miriam Quinlan, David J. Benjamin, Brett Laurence, Anandit Mu, Tiffany Ngai, Wes J. Hoffman, Stuart H. Cohen, Ian McHardy, Royce Johnson, George R. Thompson III
Arash Heidari
aKern County Medical Center, Bakersfield, California, USA
bValley Fever Institute, Bakersfield, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miriam Quinlan
aKern County Medical Center, Bakersfield, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David J. Benjamin
cDepartment of Internal Medicine, University of California Davis Medical Center, Sacramento, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brett Laurence
dSutter Medical Center, Sacramento, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anandit Mu
eDepartment of Internal Medicine, Division of Infectious Diseases, University of California San Francisco-Fresno, Fresno, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tiffany Ngai
eDepartment of Internal Medicine, Division of Infectious Diseases, University of California San Francisco-Fresno, Fresno, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wes J. Hoffman
fDepartment of Pharmacy, University of California Davis Medical Center, Sacramento, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stuart H. Cohen
gDepartment of Internal Medicine, Division of Infectious Diseases, University of California Davis Medical Center, Sacramento, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ian McHardy
hDepartment of Medical Microbiology and Immunology, University of California Davis, Davis, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ian McHardy
Royce Johnson
aKern County Medical Center, Bakersfield, California, USA
bValley Fever Institute, Bakersfield, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George R. Thompson III
gDepartment of Internal Medicine, Division of Infectious Diseases, University of California Davis Medical Center, Sacramento, California, USA
hDepartment of Medical Microbiology and Immunology, University of California Davis, Davis, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.02232-18
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Patients with coccidioidal meningitis require lifelong antifungal therapy. Cumulative toxicity and lack of antifungal efficacy require salvage therapy in the treatment of some patients. In a retrospective review of nine patients with coccidioidal meningitis treated with isavuconazole, successful therapy was seen in three patients and stable disease was confirmed in six patients. Isavuconazole may be a useful addition to the therapeutic choices currently available for coccidioidal meningitis.

INTRODUCTION

Coccidioides immitis and posadasii are dimorphic fungi endemic to the southwestern United States (1). The spectrum of disease ranges from asymptomatic acquisition with resultant immunity to severe and life-threatening disseminated infection. Disseminated infection is uncommon, occurring in only 1% to 3% of infected individuals, and is more frequent in immunocompromised individuals, women during the third trimester of pregnancy or the immediate postpartum period, or individuals of Filipino or African ancestry. Dissemination may occur to any site, although the skin, musculoskeletal system, and central nervous system (CNS) are the most frequently encountered sites (2).

CNS involvement that causes meningitis is the most serious complication and carries significant morbidity and mortality (3). Current guidelines recommend high-dose fluconazole or itraconazole in the treatment of coccidioidal meningitis (1). Limited data are available describing the efficacy of other triazoles, including voriconazole and posaconazole (4, 5). Despite the availability of these agents and the utility of polyenes or combination therapy in select cases requiring salvage therapy (6, 7), toxicity and/or lack of efficacy requires investigation of alternative agents.

Isavuconazole is a novel triazole with a broad spectrum of antifungal activity. Administered as a water-soluble prodrug, i.e., isavuconazonium sulfate, it undergoes cleavage by plasma esterases to the active moiety isavuconazole (8). Clinical trials demonstrated efficacy in the treatment of invasive aspergillosis (9), candidiasis (10), and mucormycosis (11) and in the treatment of endemic mycoses without evidence of CNS involvement (12). However, efficacy in the treatment of coccidioidal meningitis has not previously been described.

Patients with coccidioidal meningitis who received isavuconazole were identified by review of the ICD-9 and ICD-10 codes cross-referenced with pharmacy databases. Abstracted data included demographic and clinical information; results of laboratory and radiographic studies; microbiologic, pathologic, and serologic results; outcomes; and prior treatment regimens. Responses to therapy were measured with a previously validated scoring system used in clinical trials of coccidioidal meningitis (13). This scoring system combines clinical, radiographic, and cerebrospinal fluid (CSF) data to evaluate a therapeutic response, defined as a ≥40% reduction in abnormalities. Each patient was assigned a composite score at the time of isavuconazole initiation and after 3 months of therapy. The treating clinician’s assessment was also abstracted from patient medical records, and defined as success, stable, or failure.

Nine patients met criteria for inclusion (Table 1). The median patient age was 46 years, and eight of the patients were male. No comorbidities were present in this patient cohort. All patients were initiated on fluconazole as primary therapy for coccidioidal meningitis, and eight were transitioned to voriconazole, although the reasons for this change were not always identifiable on chart review. Treatment failure was found in only one patient treated with voriconazole. All other patients were transitioned from voriconazole to isavuconazole secondary to adverse effects, including photodermatitis (n = 3), photopsia (n = 1), squamous cell carcinoma (n = 1), dyspepsia (n = 1), and hepatic injury (n = 1).

View this table:
  • View inline
  • View popup
TABLE 1

Clinical characteristics, treatment, and outcomes of patients with coccidioidal meningitis treated with isavuconazole

Patient outcomes assessed with Mycosis Study Group (MSG) scoring criteria showed successful therapy in three of nine patients and stable disease in six patients. Mean time on isavuconazole therapy at last assessment was 504 days (range, 274 to 810 days) per patient. The abstracting treating clinician assessment revealed success in five of nine patients and stable disease in four patients. Discrepancies between the assessment by the treating clinician and MSG scores were seen in two patients. These differences in patient assessments were secondary to MSG criteria requiring a decrease in CSF protein to <100 mg/dL for a change in point assignment, whereas patient 4 had a decline in CSF protein from 599 to only 469 mg/dL. The second discrepant patient had a significant improvement in CSF glucose level (from 22 to 45 mg/dL) with only a moderate change in CSF white blood cell count (from 470 to 450 cells/mm3; protein values, from 2,325 to 2,006 mg/dL). No isavuconazole clinical failures were identified in this retrospective evaluation, although one patient was transitioned back to voriconazole because of worsening dyspepsia after a change to isavuconazole.

Morbidity and mortality associated with coccidioidal meningitis remain unacceptably high, and, in an attempt to prevent relapse(s), patients are maintained on lifelong antifungal therapy (14). The commitment to lifelong therapy subjects patients to cumulative toxicity, ranging from benign but irritating (e.g., xerosis, cheilitis, alopecia) (15) to more serious (e.g., fluorosis, cutaneous malignancy) (16–18) manifestations. These adverse reactions may require the use of alternative agents in attempts to improve patient compliance and tolerability.

Furthermore, despite medication compliance, relapse/breakthrough may occur (19, 20). The reasons for relapse remain unclear, and a data-driven approach to management decisions for these patients has not been presented. In cases of breakthrough fungal infection, a change in class or a change of agent is typically recommended, pending further investigation (e.g., assessment of compliance, determination of possible resistance) (21).

Cumulative toxicity and/or drug efficacy failure have necessitated the evaluation of newer antifungals. Isavuconazole is an attractive new triazole for coccidioidomycosis because of the availability of both oral and intravenous formulations, a favorable side-effect profile when directly compared with voriconazole in the treatment of invasive aspergillosis (9), and low isavuconazole MICs when evaluated against Coccidioides isolates (8, 12, 22). However, few patients with coccidioidomycosis have been treated with isavuconazole, and data have been limited to primary pulmonary infections, none with dissemination or severe manifestations of disease (12).

Despite the lack of demonstrated clinical efficacy in cases of disseminated or meningeal coccidioidomycosis, animal models of other mycoses have demonstrated the potential efficacy of isavuconazole in CNS infections (23), and early experience in human cryptococcal meningitis cases has been favorable (12). The current study establishes precedence for use in coccidioidomycosis meningitis cases with a history of treatment failure or adverse reactions to front-line antifungals.

We observed successful or stable disease in all patients included in this study, although the retrospective nature, limited duration of follow-up, and number of patients studied limit implications for wide-scale adoption. Evaluation of isavuconazole in the treatment of coccidioidomycosis would benefit from use of animal models and prospective clinical trials. The response rates observed were favorable, and isavuconazole may be a useful agent in the salvage setting for this morbid disease.

FOOTNOTES

    • Received 22 October 2018.
    • Accepted 10 December 2018.
    • Accepted manuscript posted online 17 December 2018.
  • Copyright © 2019 American Society for Microbiology.

All Rights Reserved.

REFERENCES

  1. 1.↵
    1. Galgiani JN,
    2. Ampel NM,
    3. Blair JE,
    4. Catanzaro A,
    5. Geertsma F,
    6. Hoover SE,
    7. Johnson RH,
    8. Kusne S,
    9. Lisse J,
    10. MacDonald JD,
    11. Meyerson SL,
    12. Raksin PB,
    13. Siever J,
    14. Stevens DA,
    15. Sunenshine R,
    16. Theodore N
    . 2016. 2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis. Clin Infect Dis 63:e112–e146. doi:10.1093/cid/ciw360.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Stockamp NW,
    2. Thompson GR, III.
    2016. Coccidioidomycosis. Infect Dis Clin North Am 30:229–246. doi:10.1016/j.idc.2015.10.008.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Thompson G, III,
    2. Wang S,
    3. Bercovitch R,
    4. Bolaris M,
    5. Van Den Akker D,
    6. Taylor S,
    7. Lopez R,
    8. Catanzaro A,
    9. Cadena J,
    10. Chin-Hong P,
    11. Spellberg B
    . 2013. Routine CSF analysis in coccidioidomycosis is not required. PLoS One 8:e64249. doi:10.1371/journal.pone.0064249.
    OpenUrlCrossRef
  4. 4.↵
    1. Kim MM,
    2. Vikram HR,
    3. Kusne S,
    4. Seville MT,
    5. Blair JE
    . 2011. Treatment of refractory coccidioidomycosis with voriconazole or posaconazole. Clin Infect Dis 53:1060–1066. doi:10.1093/cid/cir642.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Freifeld A,
    2. Proia L,
    3. Andes D,
    4. Baddour LM,
    5. Blair J,
    6. Spellberg B,
    7. Arnold S,
    8. Lentnek A,
    9. Wheat LJ
    . 2009. Voriconazole use for endemic fungal infections. Antimicrob Agents Chemother 53:1648–1651. doi:10.1128/AAC.01148-07.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Stewart ER,
    2. Eldridge ML,
    3. McHardy I,
    4. Cohen SH,
    5. Thompson GR, III.
    2018. Liposomal amphotericin B as monotherapy in relapsed coccidioidal meningitis. Mycopathologia 183:619–622. doi:10.1007/s11046-017-0240-7.
    OpenUrlCrossRef
  7. 7.↵
    1. Mathisen G,
    2. Shelub A,
    3. Truong J,
    4. Wigen C
    . 2010. Coccidioidal meningitis: clinical presentation and management in the fluconazole era. Medicine (Baltimore) 89:251–284. doi:10.1097/MD.0b013e3181f378a8.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    1. Thompson GR, III,
    2. Wiederhold NP
    . 2010. Isavuconazole: a comprehensive review of spectrum of activity of a new triazole. Mycopathologia 170:291–313. doi:10.1007/s11046-010-9324-3.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Maertens JA,
    2. Raad II,
    3. Marr KA,
    4. Patterson TF,
    5. Kontoyiannis DP,
    6. Cornely OA,
    7. Bow EJ,
    8. Rahav G,
    9. Neofytos D,
    10. Aoun M,
    11. Baddley JW,
    12. Giladi M,
    13. Heinz WJ,
    14. Herbrecht R,
    15. Hope W,
    16. Karthaus M,
    17. Lee D-G,
    18. Lortholary O,
    19. Morrison VA,
    20. Oren I,
    21. Selleslag D,
    22. Shoham S,
    23. Thompson GR, III,
    24. Lee M,
    25. Maher RM,
    26. Schmitt-Hoffmann A-H,
    27. Zeiher B,
    28. Ullmann AJ
    . 2016. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet 387:760–769. doi:10.1016/S0140-6736(15)01159-9.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Kullberg BJ,
    2. Viscoli C,
    3. Pappas PG,
    4. Vazquez J,
    5. Ostrosky-Zeichner L,
    6. Rotstein C,
    7. Sobel JD,
    8. Herbrecht R,
    9. Rahav G,
    10. Jaruratanasirikul S,
    11. Chetchotisakd P,
    12. Van Wijngaerden E,
    13. De Waele J,
    14. Lademacher C,
    15. Engelhardt M,
    16. Kovanda LL,
    17. Croos-Dabrera R,
    18. Fredericks C,
    19. Thompson GR, III.
    2018. Isavuconazole versus caspofungin in the treatment of candidemia and other invasive candida infections: the ACTIVE trial. Clin Infect Dis doi:10.1093/cid/ciy827.
    OpenUrlCrossRef
  11. 11.↵
    1. Marty FM,
    2. Ostrosky-Zeichner L,
    3. Cornely OA,
    4. Mullane KM,
    5. Perfect JR,
    6. Thompson GR, III,
    7. Alangaden GJ,
    8. Brown JM,
    9. Fredricks DN,
    10. Heinz WJ,
    11. Herbrecht R,
    12. Klimko N,
    13. Klyasova G,
    14. Maertens JA,
    15. Melinkeri SR,
    16. Oren I,
    17. Pappas PG,
    18. Racil Z,
    19. Rahav G,
    20. Santos R,
    21. Schwartz S,
    22. Vehreschild JJ,
    23. Young JH,
    24. Chetchotisakd P,
    25. Jaruratanasirikul S,
    26. Kanj SS,
    27. Engelhardt M,
    28. Kaufhold A,
    29. Ito M,
    30. Lee M,
    31. Sasse C,
    32. Maher RM,
    33. Zeiher B,
    34. Vehreschild M
    , VITAL and FungiScope Mucormycosis Investigators. 2016. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis 16:828–837. doi:10.1016/S1473-3099(16)00071-2.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Thompson GR, III,
    2. Rendon A,
    3. Ribeiro dos Santos R,
    4. Queiroz-Telles F,
    5. Ostrosky-Zeichner L,
    6. Azie N,
    7. Maher R,
    8. Lee M,
    9. Kovanda L,
    10. Engelhardt M,
    11. Vazquez JA,
    12. Cornely OA,
    13. Perfect JR
    . 2016. Isavuconazole treatment of cryptococcosis and dimorphic mycoses. Clin Infect Dis 63:356–362. doi:10.1093/cid/ciw305.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Galgiani JN,
    2. Catanzaro A,
    3. Cloud GA,
    4. Higgs J,
    5. Friedman BA,
    6. Larsen RA,
    7. Graybill JR
    . 1993. Fluconazole therapy for coccidioidal meningitis: the NIAID-Mycoses Study Group. Ann Intern Med 119:28–35. doi:10.7326/0003-4819-119-1-199307010-00005.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    1. Dewsnup DH,
    2. Galgiani JN,
    3. Graybill JR,
    4. Diaz M,
    5. Rendon A,
    6. Cloud GA,
    7. Stevens DA
    . 1996. Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? Ann Intern Med 124:305–310. doi:10.7326/0003-4819-124-3-199602010-00004.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    1. Pappas PG,
    2. Kauffman CA,
    3. Perfect J,
    4. Johnson PC,
    5. McKinsey DS,
    6. Bamberger DM,
    7. Hamill R,
    8. Sharkey PK,
    9. Chapman SW,
    10. Sobel JD
    . 1995. Alopecia associated with fluconazole therapy. Ann Intern Med 123:354–357. doi:10.7326/0003-4819-123-5-199509010-00006.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    Pfizer. 2018. Voriconazole package insert. Pfizer, New York, NY. http://www.pfizer.com/files/products/uspi_vfend.pdf.
  17. 17.↵
    1. Thompson GR, III,
    2. Bays D,
    3. Cohen SH,
    4. Pappagianis D
    . 2012. Fluoride excess in coccidioidomycosis patients receiving long-term antifungal therapy: an assessment of currently available triazoles. Antimicrob Agents Chemother 56:563–564. doi:10.1128/AAC.05275-11.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Epaulard O,
    2. Villier C,
    3. Ravaud P,
    4. Chosidow O,
    5. Blanche S,
    6. Mamzer-Bruneel MF,
    7. Thiebaut A,
    8. Leccia MT,
    9. Lortholary O
    . 2013. A multistep voriconazole-related phototoxic pathway may lead to skin carcinoma: results from a French nationwide study. Clin Infect Dis 57:e182. doi:10.1093/cid/cit600.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Ho J,
    2. Fowler P,
    3. Heidari A,
    4. Johnson RH
    . 2017. Intrathecal amphotericin B: a 60-year experience in treating coccidioidal meningitis. Clin Infect Dis 64:519–524. doi:10.1093/cid/ciw794.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. McHardy IH,
    2. Dinh BN,
    3. Waldman S,
    4. Stewart E,
    5. Bays D,
    6. Pappagianis D,
    7. Thompson GR, III.
    2018. Coccidioidomycosis complement fixation titer trends in the age of antifungals. J Clin Microbiol 56:e01318-18. doi:10.1128/jcm.01318-18.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Maschmeyer G,
    2. Patterson TF
    . 2014. Our 2014 approach to breakthrough invasive fungal infections. Mycoses 57:645–651. doi:10.1111/myc.12213.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Gonzalez GM
    . 2009. In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi. Med Mycol 47:71–76. doi:10.1080/13693780802562969.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Wiederhold NP,
    2. Kovanda L,
    3. Najvar LK,
    4. Bocanegra R,
    5. Olivo M,
    6. Kirkpatrick WR,
    7. Patterson TF
    . 2016. Isavuconazole is effective for the treatment of experimental cryptococcal meningitis. Antimicrob Agents Chemother 60:5600–5603. doi:10.1128/AAC.00229-16.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Download PDF
Citation Tools
Isavuconazole in the Treatment of Coccidioidal Meningitis
Arash Heidari, Miriam Quinlan, David J. Benjamin, Brett Laurence, Anandit Mu, Tiffany Ngai, Wes J. Hoffman, Stuart H. Cohen, Ian McHardy, Royce Johnson, George R. Thompson III
Antimicrobial Agents and Chemotherapy Feb 2019, 63 (3) e02232-18; DOI: 10.1128/AAC.02232-18

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Isavuconazole in the Treatment of Coccidioidal Meningitis
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Isavuconazole in the Treatment of Coccidioidal Meningitis
Arash Heidari, Miriam Quinlan, David J. Benjamin, Brett Laurence, Anandit Mu, Tiffany Ngai, Wes J. Hoffman, Stuart H. Cohen, Ian McHardy, Royce Johnson, George R. Thompson III
Antimicrobial Agents and Chemotherapy Feb 2019, 63 (3) e02232-18; DOI: 10.1128/AAC.02232-18
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Coccidioides
isavuconazole
meningitis

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596